Biofrontera Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Biofrontera Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 97% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 773% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 89% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-724.3×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 97% of Healthcare companies in United States.
Cash Locked Ratio
$8For every $100 of sales, $8 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $42 tied up three years earlier.
Less money tied up than 83% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
−$76Sales grew 45% in 3 years, but profit fell: $76 less profit per $100 of extra sales.
Lower than 85% of Healthcare companies in United States.
Asset Productivity Ratio
+45% / -44%In 3 years sales changed by +45% while total assets changed by -44%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-40.2×Operating cash was negative last year, while some debt falls due within a year.
Lower than 68% of Healthcare companies in United States.
Cash Cushion Ratio
+2%Cash, after subtracting all debt, equals 2% of its market value (net cash).
Lower than 63% of Healthcare companies in United States.
Tangible Assets Ratio
91%Of every $100 the company owns, $91 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 63% of Healthcare companies in United States.
Tangible Net Worth Ratio
75%Of every $100 of net worth, $75 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 59% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Biofrontera Inc. made a loss over the last year. Biofrontera Inc. owes $0.75 for every $1 it owns. Biofrontera Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossBiofrontera Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.95The share price is 1.95 times Biofrontera Inc.'s book value per share, lower than 60% of Healthcare companies in United States.
Market cap
$12 MThe total market value of all of Biofrontera Inc.'s shares at today's price (share price × number of shares), smaller than 86% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$6 MWhat Biofrontera Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.40Net worth divided by the number of shares. The share price of $0.78 is 1.9 times this, which is the P/B above.
Return on equity (ROE)
-988.4%Biofrontera Inc. lost 988.4% of its shareholders' money over the last year, lower than 97% of Healthcare companies in United States.
Owes vs Owns
0.75×Biofrontera Inc. owes $0.75 for every $1 it owns (moderate), higher than 75% of Healthcare companies in United States.
Dividend yield
NoneBiofrontera Inc. does not currently pay a dividend.
Revenue growth
+12%Revenue rose 12% in the year to Dec 2025, and grew 13% a year on average over 3 years.
Profit growth
LossBiofrontera Inc. made a loss in each of the last two years.
Profit margin
-25.3%Biofrontera Inc. lost $25 for every $100 of revenue.
Interest cover
Not coveredBiofrontera Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashBiofrontera Inc. held $0 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Biofrontera Inc.: $12 M ÷ $6 M (30 Jun 2026) = 1.9.
What is Biofrontera Inc.'s return on equity?
Biofrontera Inc. lost 988.4% of its shareholders' money over the last year, lower than 97% of Healthcare companies in United States.
How much does Biofrontera Inc. owe compared with what it owns?
Biofrontera Inc. owes $0.75 for every $1 it owns (moderate), higher than 75% of Healthcare companies in United States.
Does Biofrontera Inc. pay a dividend?
No. Biofrontera Inc. does not currently pay a dividend.
Is Biofrontera Inc.'s revenue growing?
Revenue rose 12% in the year to Dec 2025, and grew 13% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.